The authors provide a comprehensive summary of all randomized, controlled trials (n= 76)
involving the clinical administration of liposomal bupivacaine (Exparel; Pacira …

Background Liposomal bupivacaine is purported to extend analgesia of peripheral nerve
blocks when administered perineurally. However, evidence of the clinical effectiveness of …

Many attempts have been made to increase the duration of local anesthetic action. One
avenue of investigation has focused on encapsulating local anesthetics within carrier …

Background/Importance Liposomal bupivacaine (LB) is a prolonged release formulation of
conventional bupivacaine designed for prolonging local or peripheral regional single …

Background: Management of postoperative pain often requires multimodal approaches.
Suboptimal dosages of current therapies can leave patients experiencing periods of …

In the multimodal approach to the management of postoperative pain, local infiltration and
regional blocks have been increasingly utilized for pain control. One of the limitations of …

Background Postoperative pain remains a significant issue with poor perioperative pain
management associated with an increased risk of morbidity and mortality. Liposomal …

When physicians consider which analgesia to use postsurgery, the primary goal is to relieve
pain with minimal adverse side effects. Bupivacaine, a commonly used analgesic, has been …

Background Despite multi‐modal analgesic techniques, acute postoperative pain remains
an unmet health need, with up to three quarters of people undergoing surgery reporting …

Background Liposome bupivacaine (Exparel) is a multivesicular liposomal formulation of
bupivacaine currently approved in the United States for single-dose administration into the …